Scott Leftwich bought $250k of CLDI
director at Calidi Biotherapeutics, Inc.. 125,000 shares at an average of $2.00, traded Aug 21, 2025, filed Aug 25, 2025.
Score components
- +15RoleDirector
- +13Trade size$250k at market
- +10Relative to holdingsHoldings up 2212%
- +18Price context0% above the 52-week low; 96% below the 52-week high
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.6%, 3m -14.1%, 6m -51.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001641172-25-025446, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 21, 2025 | POpen-market purchase Common Stock | +125,000 | $2.00 | $250k | 130,650 | Aug 25, 2025 |
| Aug 21, 2025 | POpen-market purchase Warrant (right to buy)derivative | +125,000 | - | - | 125,000 | Aug 25, 2025 |
Related signals
Other insiders at Calidi Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | CLDIsell Calidi Biotherapeutics, Inc. | Allan Camaisa CEO and Chairman of the Board | $1,237 850 shares | -1% | |
| 63Notable | Calidi Biotherapeutics, Inc. | Andrew C. Jackson Chief Financial Officer | $5,000 2,500 shares | - | |
| 73Notable | Calidi Biotherapeutics, Inc. | Eric E Poma Chief Executive Officer | $50k 25,000 shares | - | |
| 69Notable | Calidi Biotherapeutics, Inc. | James A Schoeneck director | $150k 75,000 shares | +6614% | |
| 30Weak | CLDIsell Calidi Biotherapeutics, Inc. | Allan Camaisa CEO and Chairman of the Board | $16k 10,000 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.